by swvision | Dec 21, 2018 | ROP & Ranibizumab
Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity Abstract A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in...
by swvision | Dec 21, 2018 | ROP & Ranibizumab
Histopathologic Characterization of the Expression of Vascular Endothelial Growth Factor in a Case of Retinopathy of Prematurity Treated With Ranibizumab Abstract PURPOSE: To characterize the expression of vascular endothelial growth factor (VEGF) in a patient with...
